International Collaboration Announced Between UK, Canadian, and US Psychedelic Industry Leaders
For the first time, an international collaboration between psychedelic industry representatives from three jurisdictions has been agreed upon to better serve the psychedelic medicines industry.
Psychedelic Industry UK (PsyIndUK), the Canadian Psychedelic Businesses Association (PsyCan), and the Psychedelic Medicine Coalition (PMC) have officially launched a tri-party collaboration. This alliance marks the first of its kind, uniting key organisations from the United Kingdom, Canada, and the United States to foster international information sharing and drive progress in the rapidly evolving psychedelic business landscape.
The collaboration represents a major step forward for the global psychedelic sector, as these three influential groups come together to create a platform for discussion, innovation, and partnership. Going forward, PsyIndUK, PsyCan, and PMC will convene regularly to explore the latest developments in psychedelic medicines, therapies, and research. These meetings will serve as a vital opportunity for stakeholders to share insights and identify emerging opportunities for collaboration across the Atlantic.
Quote from PsyIndUK Co-Founder - James Bunn
“The formation of this tri-party alliance is a significant step forward for the global psychedelic ecosystem. By pooling our collective knowledge and fostering transatlantic collaboration, we are better positioned to address the challenges and opportunities in this industry. It’s vital that we emerge from our silos and build a unified approach that benefits patients, practitioners, and businesses alike.”
As the world becomes more interconnected, the need for international alliances in the psychedelic space has never been more important. With regulatory landscapes evolving at different paces across various countries, this collaboration will enable a more cohesive and informed approach to navigating policy, business development, and public perception.
Quote from PsyCan Executive Director - Liam Bedard
“A key focus of the collaboration will be to ensure that the psychedelic industry maintains high ethical standards. The partners will work collectively to call out bad actors and address any emerging issues that threaten the integrity of the field. By holding each other accountable and fostering transparency, the collaboration aims to promote responsible practices and bolster the industry's credibility.”
Quote from PMC Founder - Melissa Lavasani
“Psychedelic Medicine Coalition (PMC) is honored to join this groundbreaking international alliance from the very beginning. The United States plays a critical role in driving forward the global movement to ensure legitimate access to psychedelic treatments. By collaborating with our partners in the UK and Canada, we can share best practices, advocate for effective policies, and build a unified approach to advancing this industry responsibly. Together, we’re laying the foundation for a future where safe, ethical, and accessible psychedelic therapies can transform lives worldwide.”
This international partnership is a testament to the growing recognition that psychedelics are no longer a niche interest but a global movement with transformative potential. PsyIndUK, PsyCan, and PMC remain committed to creating a future where psychedelic medicine is accessible, safe, and effective for those who need it most.
We invite psychedelic industry groups from other jurisdictions to reach out to us with the intent of expanding this alliance.
About Psychedelic Industry UK:
PsyIndUK is the leading voice for the UK psychedelic sector, representing a wide range of organisations and businesses involved in the research, development, and deployment of psychedelic medicines.
About PsyCan:
PsyCan is the not-for-profit trade association of legally operating Canadian psychedelic medicine and therapy companies. We are researchers, healthcare providers, drug developers, and suppliers producing and working with psychedelic medicine. Together, we deliver psychedelic therapies through qualified professionals to treat patients suffering from a variety of health problems.
About Psychedelic Medicine Coalition:
Psychedelic Medicine Coalition (PMC) is a Washington, DC-based, nonpartisan nonprofit organization dedicated to advancing the research and implementation of psychedelic medicine treatments for healthcare in the United States through federal and state advocacy. PMC engages in conversations with federal stakeholders to spur the creation of public funding for clinical psychedelic research studies for universities, research institutions, and the industry. PMC educates elected officials, hosts Congressional briefings, convenes stakeholders, develops traditional government affairs advocacy campaigns, and provides education to advance psychedelic medicines through healthcare. Learn more at psychedelicmedicinecoalition.org
PsyIndUK is now welcoming membership applications from legitimate businesses and organisations across the industry. Members will receive a range of benefits and services, including working groups, events and networking, and advocacy.
CONTACT: James Bunn